Background: The transforming growth factor (TGF)-b pathway is a well-described inducer of immunosuppression and can act as an oncogenic factor in advanced tumors. Several preclinical and clinical studies show that the TGF-b pathway can be considered a promising molecular target for cancer therapy. The human genome has three TGF-b isoforms and not much is known about the oncogenic response to each of the isoforms. Here, we studied the antitumor response to ISTH0047, a recently developed locked nucleic acid-modified antisense oligonucleotide targeting TGF-b2.
Introduction
TGF-b is a pleiotropic cytokine with a crucial role in tissue homeostasis and embryo development. Work over recent years has shown that TGF-b can act as an oncogenic factor in advanced cancer [1] [2] [3] . TGF-b has then become an interesting therapeutic target and several pharmaceutical companies have developed anti-TGF-b compounds for the treatment of cancer [4] . However, the human genome has three TGF-b isoforms with heterogeneous expression in normal tissues and cancer [5] and, although some specific responses have been associated to individual TGF-b isoforms, not much is known about which TGF-b isoform can be a good therapeutic target.
TGF-b can act as an immunosupressor factor and tumors expressing high levels of TGF-b can escape the immune system surveillance [6, 7] implying that TGF-b inhibition might enhance an antitumor immune reaction. Specifically, TGF-b has been described to polarize tumor-associated macrophages (TAMs) toward an oncogenic phenotype [8, 9] .
Antisense oligonucleotides (ASOs) are exquisitely specific agents that have been developed as pharmacological compounds to treat cancer. Some of these ASOs, especially the more stable and less toxic derivatives known as locked nucleic acids (LNAs) [10, 11] , have reached some promising results [12] . We have developed ISTH0047, an LNA-modified TGF-b2-specific phosphorothioate ASO with a '4 þ 4' LNA gapmer pattern, formerly known as ASPH_0047 [13] , that selectively targets TGF-b2 isoform mRNA [13, 14] . In this article, we have studied the anticancer response to ISTH0047 using preclinical models. We have taken advantage of the specificity of ISTH0047 for the TGF-b2 isoform in order to accurately dissect the role of TGF-b2 in cancer and determine its potential as a therapeutic target. We found that the selective downregulation of TGF-b2 inhibits lung metastasis. ISTH0047 treatment induced CD86 expression in TAMs, a factor described to act as a tumor suppressor [15] [16] [17] . These results shed light on to the mechanism of action of TGF-b inhibitors and their impact on the tumor microenvironment allowing the further development of these promising therapies.
Materials and methods

In vivo assays
Drug reconstitution and gymnotic delivery
Lyophilized scrambled mismatch LNA-ASO (ISTH-C3) or TGF-b2-specific LNA-ASO (ISTH0047) were obtained from Isarna Therapeutics GmbH, reconstituted with 0 0 9% saline and sterilized by filtration through a 0.22-lm filter.
RNA extraction and real-time PCR
Total RNA was extracted using RNeasy (Qiagen) following manufacturer instructions. Quantitative real-time PCR (qRT-PCR) was performed on Bio-Rad CFX384 instrument with Taqman specific probes (Applied Biosystems). Each value was normalized to human GAPDH.
TGF-b ELISA immunoassay
1.5Â10
5 cells were seeded in 60-mm cell culture dishes. Twenty four hours after seeding, media was replaced by fresh medium without FBS and cells cultured for 72 hours. Culture supernatants were centrifuged at 3,000g for 5 min. TGF-b ELISAs were then performed with TGF-b1, TGF-b2 and TGF-b3 DuoSetV R (R&D) kits following manufacturer instructions.
Antibodies immunohistochemistry and immunofluorescence
TGF-b2 (Santa Cruz, sc-90), CD11b (Abcam, ab133357) and CD86 (Novus Biologicals, NBP2-12182) were used at 1:500, 1:2,000 and 1:50 dilution respectively. For CD11b, EnVision FLEX þ (DAKO) was used as a detection system. For CD86, slides were incubated with anti-rat IgG-HRP (NA935V, R&D; 1:500). For combined CD11b and F4/80 immnofluorescence, slides were blocked with 3% BSA and incubated with rat anti-mouse F4/80 (MCA497G, Serotec) at 1:20 and rabbit anti-mouse CD11b (EPR1344, abcam) 1:2,000.
In vivo assays. All animal studies were performed according to the rules and regulations of respective and relevant national ethical committees (France, Germany and Spain).
Immunocompetent Balb/c mice were injected with mouse RENCA cells into renal subcapsule on Day 0. Systemic treatment started on Day 7 for counting lung metastasis (50 mg/kg, s.c., twice weekly), or on Day 1 for lung tumor weight (12.5 mg/kg, s.c, twice weekly) for two consecutive weeks.
Mouse 4T1 breast cancer cells (10 5 cells) were orthotopically inoculated on Day 0 into the mammary fat pad of immunocompetent Balb/c mice (n¼10). Mice were treated s.c. with PBS or with 20 mg/kg of the indicated ASOs (QDÂ5, then QW)
All human CRL5807 tumors were generated in Balb/c nude mice. For s.c. tumors, 5Á10 6 CRL5807 were inoculated in the flank of the mice. 5 weeks after inoculation, mice were treated daily for 5 consecutive days with PBS, C3 or ISTH0047 s.c. at a dose of 50mg/kg (day 1) and 20mg/kg (days 2-5).
For i.v. and orthotopic experiments, CRL5807 cells expressing luciferase and transfected by gymnotic delivery with the corresponding oligodeoxynucleotide were inoculated (day 0) in the tail vein (10 6 cells) or in the lung (1.5Â10 6 cells by intercostal puncture) of mice that had been pre-treated with 15 mg/kg of oligonucleotide s.c. from day -7 to -3. A single dose of the drug was administered weekly to the mice until the end of the experiment. Tumor burden was measured using the Xenogen IVISV R Spectrum.
CD11b1 cells isolation and culture
For CD11b+ cells isolation and culture, CRL5807 tumors were cut into pieces and enzymatically digested with Mouse Tumor Dissociation kit before CD11b+ cells isolation with CD11b magnetic beads using the MultiMACS Cell24 separator Plus (all from Miltenyi Biotec), following manufacturer instructions.
More details on Materials and Methods are found in supplementary material, available at Annals of Oncology online.
Results
ISHT0047 inhibits lung metastasis
We tested the antitumor response of the TGF-b2-specific LNA-ASO, ISTH0047, using two independent mouse models of metastatic tumors generated by the orthotopic inoculation of the kidney cancer cell line, RENCA, and the breast cancer cell line, 4T1, in immunocompetent mice (syngeneic models). We first determined whether ISTH0047 inhibited TGF-b2 mRNA expression in RENCA and 4T1 cells in vitro. When cells were incubated with ISTH0047 in the absence of transfecting agents (gymnotic delivery), the levels of TGF-b2 mRNA were significantly decreased in both RENCA and 4T1. No effect of ISTH0047 was observed on TGF-b1 and TGF-b3 mRNA except for an increase in TGF-b1 and TGF-b3 mRNA levels in 4T1 cells treated with either ISTH0047 and the scrambled control (ISTH-C3) indicating an unspecific effect of the LNA-ASOs on both TGF-b isoforms ( Figure 1A ).
RENCA and 4T1 cells were orthotopically inoculated in the renal subcapsule or the mammary fat pad of mice, respectively, and generated tumors that metastasized to the lung [18] . In both models, animals were treated by s.c. administrations with ISTH0047 and ISTH-C3, and no effect on the primary tumors was detected (data not shown). However, a marked decrease in the number of lung metastasis was observed in both cases ( Figure 1B and C).
ISHT0047 inhibits TGF-b2 expression in the lung parenchyma tumor. One possibility was that the knock-down of TGF-b2 in the tumor cell was having an effect on the tumor cell ability to metastasize without impacting the tumor cell capacity to grow in the primary site. Alternatively, the decrease in TGF-b2 in the lung parenchyma could be affecting the microenvironment impairing the generation of the appropriate niche for the tumor cells to home and thrive. Supporting the second option, RENCA and 4T1 cells express very low amounts of TGF-b2 in comparison to TGF-b1 (supplementary Figure S1 , available at Annals of Oncology online), and hence TGF-b2 down-regulation in the tumor cell might not be physiologically relevant. Moreover, we observed that the LNA-ASO was distributed in different tissues including the liver, the kidney and the lung ( Figure 2A ). We used a fluorescent version of ISTH0047 and observed that 2.38% of the total signal detected in the mouse was present in the lungs ( Figure 2B ). The concentration of ISTH0047 present in the lung was 18 lg/g ( Figure 2C ). Specifically, ISTH0047 was detected in the glomeruli and Bowmann's capsules of the kidney and in alveolar and interstitial macrophages of the lung ( Figure 2D ). As expected, TGF-b2 mRNA was downregulated in the kidney and lung tissues in healthy mice treated with ISTH0047 in a consistent and sustained manner ( Figure 2E ). This indicated that the effect of ISTH0047 on lung metastasis could be mediated by the response of the lung parenchyma to the LNA-ASO.
To evaluate the differential relevance of the tumor cell or the microenvironment in the anti-metastatic response to the knockdown of TGF-b2, we decided to switch to an alternative experimental model where the tumor cell mainly expressed TGF-b2 to be able to assess the relative weight of the cell intrinsic and microenvironmental effects in the context of the down-regulation of TGF-b2 mRNA.
ISHT0047 targets TGF-b2 in CRL5807 tumors
First, we determined the expression of each TGF-b mRNA isoform in cell lines using the Cancer Cell Line Encyclopedia [19] A C (supplementary Figure S2 , available at Annals of Oncology online). Building on the previous data, we reasoned that in order to study the cell intrinsic antitumor effect of the specific inhibition of TGFb2, we should search for a tumor model that only expressed high levels of TGF-b2. In this way, we intended to prevent redundancy or interference from the other TGF-b isoforms. We analyzed the expression of TGF-b1, b2 and b3 by ELISA in several human cell lines and varying levels of TGF-b1 and TGF-b2 were detected ( Figure 3A) . None of the cell lines tested expressed significant protein levels of TGF-b3 (data not shown). In CRL5807, OV7 and A172 cells, we observed that TGF-b1 and TGF-b3 mRNAs were not affected by the transfection with ISTH0047, whereas TGF-b2 mRNA and protein levels were consistently decreased ( Figure 3B and C). We decided to pursue the study of CRL5807 as an example of a cell line mainly expressing TGF-b2 in which ISTH0047 had a pronounced effect in TGF-b2 secretion.
First, we observed no effect of ISTH0047 treatment on CRL5807 in vitro cell proliferation ( Figure 4A) . To determine the effect of ISTH0047 on the TGF-b2 transcript in vivo, we inoculated CRL5807 in mice and when the tumor was established, mice were treated with ISTH0047. We observed a non-significant increase in TGF-b2 mRNA levels in tumors when mice were treated with the control ISTH-C3 but, importantly, a substantial and statistically significant decrease of TGFb2 mRNA in tumors was observed in ISTH0047 treated mice ( Figure 4B ). These results indicated that ISTH0047 was able to markedly and selectively down-regulate TGF-b2 in tumors in vivo.
ISHT0047 affects the lung parenchyma to inhibit tumor growth
Using the CRL5807 xenograft model, we aimed to address two main questions: (i) determine the anti-tumor effect of ISTH0047 in the CRL5807 orthotopic lung cancer model and (ii) evaluate the relative contribution to the therapeutic response of the down-regulation of TGF-b2 in tumor cells as compared with the down-regulation of TGF-b2 in the stroma.
To address both questions, we combined two types of experimental procedures. In one type of experiments, we inoculated the tumor cells through the tail vein and assessed tumor cell homing and growth in the lung recapitulating some aspects of the process of lung metastasis. In the other type of experiments, we inoculated the tumor cells directly in the lung parenchyma bypassing tumor cell homing and assessing tumor growth in the lung. In both cases, we treated the tumor-bearing animals with LNAASOs. In this way, the LNA-ASO had an impact on both the tumor stroma and the tumor cell. In the case of the orthotopic inoculation, we also carried out gymnotic delivery of the LNAASOs to CRL5807 cells before their inoculation in untreated mice to study the effect of the down-regulation of TGF-b2 on the tumor cell but not on the stroma. When we inoculated tumor cells (either i.v. administration or orthotopically into the lung) and the animals were treated with ISTH0047 (down-regulating TGF-b2 in both the tumor stroma and tumor cell) we observed a decrease in the size of the lung lesions ( Figure 4C and D) . Interestingly, when we treated tumor cells and not the animals with ISTH0047, we did not observe a decrease in tumor growth when cells were orthotopically inoculated into the lung ( Figure 4D , fifth condition). This indicated that only when the animals were treated with ISTH0047 (not when only tumor cells were treated), we observed an anti-tumor response ( Figure 4D , fifth versus sixth condition). This led to the conclusion that the stroma was extremely relevant in the antitumor response to TGF-b2.
ISHT0047 treatment induced the expression of CD86 in TAMs
Something in the lung tissue (not in the tumor cell) was responding to ISTH0047 and preventing tumor growth. The obvious hypothesis was that the immune system, well described to be modulated by TGF-b, could be affected by the TGF-b2 knockdown. Balbc/nu mice (the mice used in the CRL5807 xenograft models) lack the T-cell compartment but exhibit functional NK and myeloid cells. Myeloid cells, and in particular TAMs, are regulated by TGF-b. We decided to study macrophages and observed that in our model most of the CD11bþ cells are F4/80þ (supplementary Figure S3 , available at Annals of Oncology online ) showing that they are highly enriched in macrophages. We observed that CD11bþ macrophages from healthy lungs and TAMs from the CRL5807 tumors expressed similar levels of TGF-b2 (supplementary Figure S4 , available at Annals of Oncology online ).
We studied the effect of ISTH0047 on TAM gene expression and, specifically, we determined the levels of CD86, a welldescribed tumor suppressive factor [15-17, 20, 21] . Using flow cytometry, we observed a significant increase in CD86þ cells in the CD11bþ compartment in mice treated with ISTH0047 ( Figure  5A ). Moreover, we decided to isolate the CD11bþ cells and assess the levels of CD86 transcript. Again, we observed an increase in CD86 mRNA levels upon ISTH0047 treatment ( Figure 5B ). These results were confirmed when we analyzed the presence of CD86þ cells in ISTH0047 treated tumors by IHC ( Figure 5C ). Finally, we carried out fresh cultures of TAMs that were treated with conditioned media from CRL5807 expressing a shRNA targeting TGFb2 ( Figure 5D ). TAMs cultured with conditioned media from CRL5807 in which we knocked down TGF-b2 experienced a 4-fold increase in the expression of CD86 and a decrease in ARG1 (used here as a control) ( Figure 5E ). This observation was concomitant with an increase in the expression of CD86 in the membrane of TAMs as detected by flow cytometry ( Figure 5F ). In summary, our data indicated that the down-regulation of TGF-b2 re-educated TAMs cells toward a CD86þ phenotype.
Discussion
Here, we focused our efforts on the study of the TGF-b pathway as a therapeutic target and in particular of one of the TGF-b isoforms, TGF-b2. We found that a LNA-ASO specifically targeting TGF-b2 (ISTH0047) inhibited lung metastasis but not primary tumor growth in two syngeneic orthotopic cancer models that generate metastasis in the lung, the murine renal cell carcinoma RENCA, and the breast 4T1 xenograft models. In order to dissect the molecular mechanisms underlying the antimetastatic effect of ISTH0047, we used the human lung cancer Before cell inoculation, animals were treated with ISTH-C3 or with ISTH0047 for 5 consecutive days and once a week afterward. An untreated group of animals was also included in the experiment. Lung tumor burden was measured by IVIS after i.v. and orthotopic lung inoculation (n ¼ 6-8 mice per group). Results were analyzed with a non-parametric two independent samples Wilcoxon-Mann-Whitney statistical analysis (two-sided P value) *P < 0,05; **P < 0,01. cell line CRL5807 that only expresses high levels of TGF-b2 and not the other TGF-b isoforms. In this sense, we studied TGF-b2 avoiding the interference of the other isoforms.
We observed that the inhibition of TGF-b2 expression prevents the growth of lung lesions in our CRL5807 cancer model by impacting on the tumor stroma. Blockade of TGF-b2 in the tumor cell did not significantly impact on tumor growth once we directly implanted the CRL5807 cells in the lung parenchyma. The stromal TGF-b2 had to be decreased in order to observe an antitumor response.
Specifically, we observed that the inhibition of TGF-b2 induced the expression of the CD86 marker in TAMs ( Figure  5G ). Interestingly, it has been widely described how TAMs play a crucial role in establishing the pre-metastatic niche [22, 23] and particularly relevant is the fact that CD86 has been described to act as a suppressive factor [15] [16] [17] 21] .
Using ISTH0047 as a tool to dissect the role of TGF-b2 in the tumor cell or the stroma, we have shown that stromal TGF-b2 can be a promising therapeutic target to inhibit lung metastasis.
Moreover, thanks to the exquisite specificity of LNA-ASOs, we have been able to discern the molecular mechanisms implicated in the inhibition of TGF-b2. Our work indicates that TGF-b2 is an appealing therapeutic target in cancer impacting the tumor microenvironment and that LNA-ASOs could be promising compounds to achieve the specific inhibition of TGF-b2.
Overall our data open a wide avenue of possibilities for the development of anticancer agents based on the selective inhibition of TGF-b. 
